Dramatic response of brain metastasis from EGFR-mutation-positive NSCLC to dacomitinib

Kenichiro Kudo, Keita Kawakado, Tomoka Kawajiri, Tatsuya Nishi, Go Makimoto, Tomoki Tamura, Shoichi Kuyama, Mitsune Tanimoto

Research output: Contribution to journalArticlepeer-review

6 Citations (Scopus)


The central nervous system efficacy of dacomitinib, a key agent used in the treatment of epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC), is unclear. We herein present our experience in the use of dacomitinib for the treatment of multiple brain metastatic lesions from EGFR-mutationpositive NSCLC in an elderly patient. This case report demonstrates that dacomitinib can be an essential treatment option for patients with brain metastases.

Original languageEnglish
Pages (from-to)1739-1740
Number of pages2
JournalInternal Medicine
Issue number14
Publication statusPublished - Jul 15 2020
Externally publishedYes


  • Brain metastasis
  • Dacomitinib
  • Non-small cell lung cancer

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Dramatic response of brain metastasis from EGFR-mutation-positive NSCLC to dacomitinib'. Together they form a unique fingerprint.

Cite this